The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk
Fairfax, Va. (PRWEB) July 8, 2009
PharmSource Information Services, Inc., a respected provider of business intelligence on contract drug development and manufacture, is pleased to announce the publication of a new white paper - "The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk." This incisive resource provides guidelines on how to establish a strong FCPA compliance program that minimizes corruption risk for companies doing business throughout the world.
"The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk" is valued at $495, but will be offered as a free download for a limited time only, from July 8 through July 21, 2009 at http://www.pharmsource.com/white-paper. This proprietary white paper includes detailed information on:
- Industry-specific implications of current FCPA regulations.
- Essential elements of a strong FCPA compliance program for those in the bio/pharma industry.
- Comprehensive steps to implement a solid FCPA compliance program.
- Enforcement of anti-corruption business practices in emerging markets.
- Mechanisms to avoid compliance pitfalls despite global and economic challenges.
"This report provides priceless strategic insights on FCPA compliance programs, which could save bio/pharma companies millions of dollars in fines and losses due to an unintended corruption scandal," advises PharmSource founder and president, Jim Miller.
The U.S. is increasing the number of investigations of FCPA and financial fraud violations, particularly within the pharmaceutical sector. This has been reflected by an increase in enforcement budgets and the employment of additional personnel to improve the frequency with which investigations are conducted. Readers will find this timely publication to be a critical first step in understanding FCPA practices and ensuring the protection afforded by a robust compliance program, especially while conducting business in emerging markets.
"[After all], it is far easier to start a compliance program before commencing work overseas than it is to implement one retroactively, but it is also far more cost-effective to implement and run a compliance program than it is to be involved in any kind of FCPA investigation, which not only is costly but can have devastating effects on a company's reputation and business," comments Leslie McCarthy, director of corporate development at The STEELE Foundation, in the white paper.
If you would like to obtain a copy of "The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk," please contact PharmSource via e-mail at [email protected] or call 1-703-383-4903 (USA ET).
PharmSource is a respected provider of business intelligence on contract drug development and manufacture. A premier information resource for both biotechnology/pharmaceutical sourcing executives and contract service providers since 1996, PharmSource has provided organizations involved in contract pharma services with publications, databases, surveys and consulting services. Companies from around the world continually rely on PharmSource's deep industry expertise and analyses to help them make smarter strategic business decisions.
About PharmSource ADVANTAGE
PharmSource ADVANTAGE online service is one of the industry's most respected outsourcing information web portals for serious consumers of information on contract drug development and manufacturing. This strategic resource allows subscribers to receive industry insight and analysis through two regular publications - Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report. It also includes full access to PharmSource's highly regarded database of contract service providers, where subscribers can search for and compare hundreds of companies from around the world that serve the pharma industry.